FDA Approves Genentech’s Immunotherapy For People With Certain Types Of Early-Stage Lung Cancer
October 15th, 2021
On October 15, 2021, the FDA approved Tecentriq® (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for adults with Stage II-IIIA non-small cell lung cancer (NSCLC) whose tumors express PD-L1≥1%, as determined by an FDA-approved test.
News in brief
- Tecentriq is the first and only cancer immunotherapy approved for treatment of NSCLC in the adjuvant setting
- Approval based on the Phase III IMpower010 study showing adjuvant Tecentriq improved disease-free survival by more than one-third in PD-L1-positive Stage II-IIIA lung cancer, compared with best supportive care
Supporting Information
“Tecentriq is now the first and only cancer immunotherapy available for adjuvant treatment of NSCLC, introducing a new era where people diagnosed with early lung cancer may have the opportunity to receive immunotherapy to increase their chances for cure. Today’s landmark approval gives physicians and patients a new way to treat early lung cancer that has the potential to significantly reduce risk of cancer recurrence after more than a decade with limited treatment advances in this setting.”